Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series

Background/aim Biologics represent a key therapeutic option in inflammatory bowel disease (IBD), but are associated with several side effects. Post-marketing surveillance, through a spontaneous adverse drug reactions (ADRs) monitoring system, is essential to assess the safety profile of biologics. The aim of the study was to prospectively evaluate the occurrence of ADRs in IBD patients treated with biologics from a single centre in Southern Italy. Methods Data from patients with Crohn's Disease (CD) and Ulcerative Colitis (UC) who underwent biological therapy were prospectively collected. ADRs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA®). Results Overall, 68 (54% male, 68% with UC and 32% with CD) biologic-naïve IBD patients underwent biological therapy. Mean follow-up was 11.7 ± 6.2 months. As a results of switches, for 68 patients we obtained 96 biologic prescriptions. Overall, 45 ADRs occurred in 36 (53%) patients, distributed as follows (ADRs/prescriptions): 19/37 with IFX-Remicade, 5/12 with IFX-Remsima, 8/9 with GOL, 11/26 with ADA, and 2/12 with VDZ. Mild ADRs were 29 (64%), moderate 15 (34%) and 1 (2%) severe. General disorders and administration related reactions were the most frequent ADRs (35%), followed by skin and subcutaneous tissue disorders (20%), infections (15%), musculoskeletal (11%), respiratory (6%) blood (4%), gastrointestinal (4%), and vascular disorders (2%). In 9 cases (20%) the ADRs resulted in definitive discontinuation of biologic therapy. Conclusion In a prospective cohort of IBD patients, more than half experienced ADRs during biologic therapy. General disorders and administration related reactions were the most common ADRs, while infections were less common and rarely led to discontinuation of therapy. Findings underline the importance of surveillance in management of IBD patients during biologic therapy and implementing safety protocols with data from real-life settings.

[1]  Edoardo Spina,et al.  Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy , 2020, Current medical research and opinion.

[2]  M. Mosli,et al.  Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study , 2020, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[3]  J. Axelrad,et al.  The Complex Interplay Between Inflammatory Bowel Disease and Malignancy , 2020, Current Gastroenterology Reports.

[4]  J. Rahier,et al.  Predicting, Preventing, and Managing Treatment-related Complications in Patients With Inflammatory Bowel Diseases. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  M. Parkes,et al.  Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience , 2020, Annals of gastroenterology.

[6]  M. Parkes,et al.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults , 2019, Gut.

[7]  A. Tursi,et al.  Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. , 2019, European journal of internal medicine.

[8]  Siddharth Singh,et al.  Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2019, Journal of Crohn's & colitis.

[9]  A. Tursi,et al.  Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers , 2019, Annals of gastroenterology.

[10]  N. Bhala,et al.  Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease , 2019, Alimentary pharmacology & therapeutics.

[11]  S. Vermeire,et al.  New biologics and small molecules in inflammatory bowel disease: an update , 2019, Therapeutic advances in gastroenterology.

[12]  J. Bae,et al.  Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population‐based cohort study , 2018, Alimentary pharmacology & therapeutics.

[13]  W. Sandborn,et al.  Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience , 2018, Inflammatory bowel diseases.

[14]  S. Magina,et al.  Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients , 2018, Digestive Diseases and Sciences.

[15]  M. Murad,et al.  Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis , 2018, Alimentary pharmacology & therapeutics.

[16]  C. Prati,et al.  "Paradoxical" arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease. , 2018, Joint, bone, spine : revue du rhumatisme.

[17]  A. Tursi,et al.  Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers. , 2017, Journal of gastrointestinal and liver diseases : JGLD.

[18]  A. Griffiths,et al.  Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.

[19]  G. García,et al.  Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study , 2016, World journal of gastroenterology.

[20]  S. Bonovas,et al.  Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  D. Margolis,et al.  Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. , 2016, JAMA dermatology.

[22]  Wei Li,et al.  Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials , 2016, Gut and liver.

[23]  M. Färkkilä,et al.  Infliximab-induced skin manifestations in patients with inflammatory bowel disease , 2016, Scandinavian journal of gastroenterology.

[24]  P. Kawalec,et al.  Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials , 2016, Clinical Drug Investigation.

[25]  G. Castellano-Tortajada,et al.  Pharmacologic therapy for inflammatory bowel disease refractory to steroids , 2015, Clinical and experimental gastroenterology.

[26]  B. Weiss,et al.  Infliximab-Related Infusion Reactions: Systematic Review , 2015, Journal of Crohn's & colitis.

[27]  W. Harmsen,et al.  Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. , 2015, Mayo Clinic proceedings.

[28]  Yuehong Chen,et al.  Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses , 2015, Clinical Rheumatology.

[29]  R. Alberts,et al.  Performance of the Montreal classification for inflammatory bowel diseases. , 2014, World journal of gastroenterology.

[30]  M. Silverberg,et al.  Future directions in inflammatory bowel disease management. , 2014, Journal of Crohn's & colitis.

[31]  P. Munkholm,et al.  Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. , 2014, JAMA.

[32]  Eun Sun Kim,et al.  Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti-Tumor Necrosis Factor-α Therapy , 2014, Yonsei medical journal.

[33]  A. Moss,et al.  Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.

[34]  L. Guidi,et al.  Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[35]  J. Colombel,et al.  Skin Side Effects of Inflammatory Bowel Disease Therapy , 2013, Inflammatory bowel diseases.

[36]  A. Ananthakrishnan,et al.  Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. , 2013, Journal of Crohn's & colitis.

[37]  Christopher F. Martin,et al.  Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[38]  Christopher F. Martin,et al.  Increased Risk of Pneumonia Among Patients With Inflammatory Bowel Disease , 2013, The American Journal of Gastroenterology.

[39]  S. Vermeire,et al.  Paradoxical inflammation induced by anti-TNF agents in patients with IBD , 2012, Nature Reviews Gastroenterology &Hepatology.

[40]  J. Andrews,et al.  Serious infections in patients with inflammatory bowel disease receiving anti‐tumor‐necrosis‐factor‐alpha therapy: An Australian and New Zealand experience , 2010, Journal of gastroenterology and hepatology.

[41]  D. M. van der Heijde,et al.  The joint-gut axis in inflammatory bowel diseases. , 2010, Journal of Crohn's & colitis.

[42]  E. Cabré,et al.  Infliximab safety profile and long‐term applicability in inflammatory bowel disease: 9‐year experience in clinical practice , 2010, Alimentary pharmacology & therapeutics.

[43]  M. Picco.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2009 .

[44]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[45]  D. Mutasim,et al.  Skin manifestations of inflammatory bowel disease. , 2008, Clinics in dermatology.

[46]  A. Zinsmeister,et al.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.

[47]  S. Plevy,et al.  The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.